Compare Nippon India Pharma Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.82 | 1.86 |
NAV | ₹488.48 | ₹37.81 |
Fund Started | 10 May 2004 | 25 Jun 2018 |
Fund Size | ₹8264.71 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.82
1.86
NAV
₹488.48
₹37.81
Fund Started
10 May 2004
25 Jun 2018
Fund Size
₹8264.71 Cr
₹6455.55 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
1 Year | -2.24% | -1.54% |
3 Year | 20.26% | 25.69% |
5 Year | 13.74% | 16.06% |
1 Year
-2.24%
-1.54%
3 Year
20.26%
25.69%
5 Year
13.74%
16.06%
Equity | 97.37% | 97.87% |
Cash | 2.62% | 2.13% |
Equity
97.37%
97.87%
Cash
2.62%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 13.02% |
Lupin Ltd. | 7.36% |
Divi's Laboratories Ltd. | 6.58% |
Cipla Ltd. | 6.39% |
Dr. Reddy's Laboratories Ltd. | 6.02% |
Apollo Hospitals Enterprise Ltd. | 5.53% |
Vijaya Diagnostic Centre Ltd. | 3.71% |
Medplus Health Services Ltd. | 3.54% |
Ajanta Pharma Ltd. | 3.21% |
Sai Life Sciences Ltd. | 2.81% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 May 2004 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 May 2004
25 Jun 2018